792 related articles for article (PubMed ID: 23040208)
1. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
3. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
Greenspan SL; Nelson JB; Trump DL; Resnick NM
Ann Intern Med; 2007 Mar; 146(6):416-24. PubMed ID: 17371886
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
6. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
Greenspan SL; Nelson JB; Trump DL; Wagner JM; Miller ME; Perera S; Resnick NM
J Clin Oncol; 2008 Sep; 26(27):4426-34. PubMed ID: 18802155
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
8. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
10. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
11. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
[TBL] [Abstract][Full Text] [Related]
12. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
14. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
15. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
17. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Clemmesen B; Christiansen C
Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
20. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
